secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001213900-25-073130
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada reports Q2 net loss $9.9M; NDV-01 91% overall response rate in NMIBC
----------------------------------------------------------------------------

- Q2 net loss $9.9M ($0.30/shr) vs $17.8M ($0.59) a year ago; R&D expense fell to $2.8M from $10.7M.
- NDV-01 Phase 2: 91% complete response at any time; 90% at 6 months; no Grade 3+ TRAEs or discontinuations.
- Cash $20.6M at June 30, 2025, down from $44.9M at Dec 31, 2024; shares outstanding 33.2M.
- Phase 3 registration trial for NDV-01 planned for 1H 2026; Phase 2 for sepranolone in PWS in 1H 2026.
- No patients progressed to muscle-invasive disease or underwent cystectomy in the study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025073130/0001213900-25-073130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025073130/ea0252310-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-073130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer